<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592458</url>
  </required_header>
  <id_info>
    <org_study_id>A-SOP-CT-001</org_study_id>
    <nct_id>NCT04592458</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients</brief_title>
  <official_title>A Single Center, Open Label Study to Evaluate the Safety and Efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BGI-research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BGI-research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study to evaluate the safety and efficacy of β-globin Restored&#xD;
      Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with ß-Thalassemia major will be recruited and their autologous hematopoietic stem&#xD;
      cells will be collected and modified with LentiHBBT87Q system to restore the β-globin&#xD;
      expression. After conditioning, the β-globin restored autologous hematopoietic stem cells&#xD;
      will be infused back to patients, and a 2 years follow up visit will be conducted and the&#xD;
      data will be collected. Participants in this study will be also asked to participant in a&#xD;
      subsequent follow up study that will monitor the long-term safety and efficacy of the&#xD;
      treatment for up to 13 years post-transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>0-100 days</time_frame>
    <description>The number and the percentage of adverse events related to transplantation in 100 days will be summarized according to NCI CTCAE 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>0-24 months</time_frame>
    <description>Number of patients alive through the whole trial will be record.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of engraftments</measure>
    <time_frame>0-24 months</time_frame>
    <description>Neutrophil count [ANC] &gt;=500 /mm3 for 3 consecutive days and platelet count [PLT] &gt;20,000/mm3 for7 consecutive days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Replication competent lentivirus (RCL)</measure>
    <time_frame>0-24 months</time_frame>
    <description>The percentage of RCL should be negative in the 24 months after transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamics of viral integration sites (VIS)</measure>
    <time_frame>0-24 months</time_frame>
    <description>Evaluation of the percentage of participants without abnormal clonal proliferation and polyclonal engraftment at 6, 12, 18 and 24 months after transplant. More than 1000 VIS retrieved from peripheral blood should be checked.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average Insertion copy number (VCN) in peripheral blood mononuclear cells</measure>
    <time_frame>18-24 Months</time_frame>
    <description>The average insertion copy number (VCN) should be ≥0.1 in peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The expression level of exogenous adult hemoglobin</measure>
    <time_frame>18-24 Months</time_frame>
    <description>Exogenous adult hemoglobin will be evaluated by globin chains and hemoglobin synthesis on peripheral blood by HPLC and the exogenous adult hemoglobin level is ≥2.0g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in annualized frequency and volume of packed RBC transfusions</measure>
    <time_frame>18-24 Months</time_frame>
    <description>Compare the annualized number of pRBC transfusions before gene therapy with the Month 6 and Month 24 period after transplant, the percentage change will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>β-Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 transfusion dependent β-thalassemia major subjects who are 8-16 years older will be transplanted with β-globin restored autologous hematopoietic stem cells that are modified with lentiviral vector LentiHBBT87Q encoding the human β-globin gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>β-globin restored autologous HSC</intervention_name>
    <description>β-globin restored autologous HSC modified with lentiviral vector LentiHBBT87Q</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  8-16 years old. Subject and/or subject's legal guardian fully understand and&#xD;
             voluntarily sign informed consent;&#xD;
&#xD;
          -  Clinically diagnosed as transfusion-dependent β-thalassemia major;&#xD;
&#xD;
          -  With sufficient RBC infusion, subjects must maintain hemoglobin ≥9g/dL, serum ferritin&#xD;
             threshold ≤ 3000 ng/mL and the liver iron overload mild or absent for at least 3&#xD;
             months before mobilization of hematopoietic stem cell;&#xD;
&#xD;
          -  Follow the arrangements for treatment and regular medical checks within two years&#xD;
             post-transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The physical condition does not meet the requirements for hematopoietic stem cell&#xD;
             mobilization and transplantation myeloablation;&#xD;
&#xD;
          -  Received gene therapy and allogeneic HSCT in the past.&#xD;
&#xD;
          -  Have an available HLA matched donor.&#xD;
&#xD;
          -  Enrolling in another clinical trial.&#xD;
&#xD;
          -  Other unsuitable conditions identified by doctors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chao Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BGI-research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sixi Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Li, PhD</last_name>
    <phone>13510560664</phone>
    <email>lijing4@genomics.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Genomics Institute At Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518083</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Li, PhD</last_name>
      <phone>+8613510560664</phone>
      <email>lijing4@genomics.cn</email>
    </contact>
    <investigator>
      <last_name>Chao Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sixi Liu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>β-thalassemia major</keyword>
  <keyword>β-globin restoration</keyword>
  <keyword>autologous HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

